StreetInsider.com News Articles

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients

Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)

Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient

Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy

Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

Wed, 26 Aug 2026 11:45:00 -0400

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients
Original research conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA)
Authors document major clinical impact in the early diagnosis of esophageal and gastric cancers: dysplasia detected in nearly three times as many patients in Barrett’s esophagus surveillance, with 48.5% fewer biopsies per patient
Endomicroscopy characterized as safe and accurate adjunct to standard upper gastrointestinal endoscopy
Systematic reviews with meta-analyses are among the strongest clinical evidence used by guideline committees and payers

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth:

Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital

Fri, 07 Aug 2026 11:45:00 -0400

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)
Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)
Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)
Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)
International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Tue, 21 Jul 2026 11:45:00 -0400

H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1
CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion
Strong systems pipeline for H2 2026 in the U.S. and new international territories
Confirmed trajectory toward profitability by year-end 2027 supported by sales growth and strengthened balance sheet
Webinar for shareholders and investors – Tuesday, July 21, 2026

5:50 p.m. (CEST) – French Session: Click here to register

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and